Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03753659
Title IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications

hepatocellular carcinoma

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.